Research at Decision Biomarkers has led to technology breakthroughs in microarray surface chemistry, immunoassay automation and detection optics. Our proprietary technologies include an enabling surface coating for protein binding, a unique reagent delivery system for ELISA automation and a novel microarray imaging system

What We Offer

We have combined our expertise and technology innovations to develop the AVANTRA™Q400 biomarker workstation, the first multiplex immunoassay system to deliver high-precision results for biomarker panels. Our system offers unmatched sensitivity, accuracy, ease-of-use, assay dynamic range, and low capital cost.

Our Goal

Multiplex protein biomarker analysis is becoming increasingly important as a tool in the drug development process as scientists continue to understand the complex nature of diseases. In developing our technologies and creating the AVANTRA™Q400 biomarker workstation, our goal is to address the unmet needs currently impacting the development lifecycle within the pharmaceutical and biotech industries; namely, increased requirements for data accuracy and precision, particularly as biomarker screening begins to transition to validation and clinical deployment.